Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib Induction + ASCT vs ASCT Alone in AL Amyloidosis
NCT01998503Phase 3Completed
- Sponsor
- Nanjing University School of Medicine
- Start
- Dec 2007
- Primary completion
- Jun 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib in amyloid light chain amyloidosis (2 arms), sponsored by Nanjing University School of Medicine. Primary endpoint: Number of participants with hematologic complete response at 12 months. Started Dec 2007; status: completed.
02
Drugs
bortezomib
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT01998503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01998503.